Jump to content

Nadolol: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
Leo2618 (talk | contribs)
15 edits
Leo2618 (talk | contribs)
15 edits
Line 57: Line 57:
==Indications==
==Indications==


Nadolol has FDA approved indications for the treatment of [[hypertension]] and for the long-term treatment of [[angina pectoris]].<ref>[[Drug Facts And Comparisons]]. 2011 Edition. Wolters Kluwer Health, 77 Westport Plaza, Suite 450, St. Louis, Missouri. (4)775.</ref>
Nadolol has [[FDA]] approved indications for the treatment of [[hypertension]] and for the long-term treatment of [[angina pectoris]].<ref>[[Drug Facts And Comparisons]]. 2011 Edition. Wolters Kluwer Health, 77 Westport Plaza, Suite 450, St. Louis, Missouri. (4)775.</ref>


==Off-Label Uses==
==Off-Label Uses==

Revision as of 14:55, 17 February 2011

Nadolol
Clinical data
Routes of
administration		Oral
ATC code
Legal status
Legal status
Pharmacokinetic data
Protein binding30%
MetabolismNil
Elimination half-life14-24 hours
ExcretionRenal and fecal (unchanged)
Identifiers
  • (2R,3S)-5-{[(2R)-3-(tert-butylamino)-2-hydroxypropyl]oxy}-1,2,3,4-tetrahydronaphthalene-2,3-diol
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.050.625 Edit this at Wikidata
Chemical and physical data
FormulaC17H27NO4
Molar mass309.401 g/mol g·mol−1
3D model (JSmol)
  • OC(CNC(C)(C)C)COc1cccc2c1C[C@H](O)[C@H](O)C2
  • InChI=1S/C17H27NO4/c1-17(2,3)18-9-12(19)10-22-16-6-4-5-11-7-14(20)15(21)8-13(11)16/h4-6,12,14-15,18-21H,7-10H2,1-3H3/t12?,14-,15+/m1/s1 checkY
  • Key:VWPOSFSPZNDTMJ-UCWKZMIHSA-N checkY
  (verify)

Nadolol (Corgard, Anabet, Solgol, Corzide, Alti-Nadolol, Apo-Nadol, Novo-Nadolol) is a non-selective beta blocker used in the treatment of high blood pressure, migraine headaches, and chest pain.

Chemistry

Nadolol is polar and hydrophilic, with low lipid solubility.

Pharmacology

Main article: Beta-blocker

Nadolol is a non-selective beta blocker; that is, it non-selectively blocks both beta-1 and beta-2 receptors. It has a preference for beta-1 receptors, which are predominantly located in the heart, thereby inhibiting the effects of catecholamines and causing a decrease in heart rate and blood pressure. Its inhibition of beta-2 receptors, which are mainly located in the bronchial smooth muscle of the airways, leads to airway constriction similar to that seen in asthma. Inhibition of beta-1 receptors in the juxtaglomerular apparatus of the kidney inhibits the renin-angiotensin system, causing a decrease in vasoconstriction and a decrease in water retention. Nadolol's inhibition of beta-1 receptors in the heart and kidney lead to its effects on lowering blood pressure.

The drug impairs AV node conduction and decreases sinus rate.

Nadolol may also increase plasma triglycerides and decrease HDL-cholesterol levels.

Indications

Nadolol has FDA approved indications for the treatment of hypertension and for the long-term treatment of angina pectoris.[2]

Off-Label Uses

Nadolol is used for the prevention of migraine headaches for which there is good documentation.[3]A case report study from Harvard Medical School, published in 1991, described three adult patients with ADHD unsuccessfully treated with traditional psychostimulant (amphetamine) therapy due to lack of effectiveness or intolerance of the psychostimulant. Nadolol was then added to the psychostimulant therapy and the combination of medications resulted in improved attention and focus with decreased medication side effects. This suggested the combination of nadolol and the psychostimulant might be effective for treatment-resistant adults with ADHD.[1]

Contraindications

Patients whose heart rate is largely mediated by the sympathetic nervous system (e.g. patients with congestive heart failure or myocardial infarct) should avoid nadolol as it inhibits sympathetic function. Nadolol is also contraindicated in patients with bradycardia (slow heart rate) because of its vasodilatory effects and tendency to cause bradycardia.

Because of its beta-2 activity, nadolol causes pulmonary bronchoconstriction and should be avoided in asthma patients in preference of a beta-1 blocker. (There may be new evidence indicating that long-term non-selective beta-blocker use may actually prove to be beneficial in mild asthma.[4])

As nadolol, like other beta-2 blockers, inhibits the synthesis and release of glucose in response to hypoglycemia, it slows patients' recovery from acute hypoglycemic episodes and should be avoided in patients getting treatment for their diabetes mellitus. In patients with insulin-dependent diabetes, a selective beta-1 blocker is preferred over non-selective blockers.

Side Effects

See also

References

  1. ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
  2. ^ Drug Facts And Comparisons. 2011 Edition. Wolters Kluwer Health, 77 Westport Plaza, Suite 450, St. Louis, Missouri. (4)775.
  3. ^ Drug Facts And Comparisons. 2011 Edition. Wolters Kluwer Health, 77 Westport Plaza, Suite 450, St. Louis, Missouri. (4)775
  4. ^ http://ajrcmb.atsjournals.org/cgi/content/full/38/3/249

^ Buice RG, Subramanian VS, Duchin KL, Uko-Nne S. (1996). "Bioequivalence of a highly variable drug: an experience with nadolol". Pharmaceutical Research. 13 (7): 1109–15. doi:10.1023/A:1016031313065. PMID 8842054.{{cite journal}}: CS1 maint: multiple names: authors list (link) ^N. Hanania, S. Singh, R. El-Wali, et al. The safety and effects of the beta-blocker, nadolol, in mild asthma: An open-label pilot study Pulmonary Pharmacology & Therapeutics, Volume 21, Issue 1, Pages 134-141

Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Nadolol&oldid=414440756"